N. Carolina to Get 85,000 Initial Pfizer COVID Vaccine Doses | North Carolina News


By BRYAN ANDERSON, Associated Press/Report for America

RALEIGH, N.C. (AP) — North Carolina Gov. Roy Cooper announced on Tuesday that the state will soon receive about 85,000 doses of Pfizer’s COVID-19 vaccine from the federal government.

His health secretary, Dr. Mandy Cohen, said she anticipates the federal government will provide the first allotment as early as Dec. 15, with additional doses being distributed to states on a weekly basis.

Hospital workers will be the first to receive the vaccine in North Carolina, according to Cooper and Cohen. Other healthcare workers and nursing home residents will be next in line. Residents who self-report at least two serious underlying health issues will be prioritized next.

“Healthcare workers, people in long-term care and those at risk for severe illness will come first,” Cooper said in a news conference. “But when it’s my turn to get this vaccine, I’ll be ready to roll up

Read More

Vision Marine Technologies Announces Closing of Initial Public Offering of Common Shares and Full Exercise of Underwriters Over-Allotment Option


Montreal, Canada – ( NewMediaWire ) – November 27, 2020 – Vision Marine Technologies Inc. (Nasdaq: VMAR), the leading provider of electric technology in the design and manufacture of the first fully electric powertrain outboard motor (E-Motion) and electric power boats, today announced the closing of its initial public offering of 2,760,000 common shares at a price of US$10.00 per share, which includes 360,000 shares sold upon full exercise of the underwriter’s option to purchase additional common shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were US$27,600,000, before deducting underwriting discounts, commissions and offering expenses. 

ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.  

Vision intends to use the net proceeds from the offering for sales and marketing, build-up of inventory for order fulfillment, research and development, development of rental operations, and general working capital.

A registration

Read More

Tiga Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Units


SINGAPORE–(BUSINESS WIRE)–Nov 27, 2020–

Tiga Acquisition Corp. (the “Company”) (NYSE: TINV.U) today announced the closing of its initial public offering of 27,600,000 units, which includes 3,600,000 units issued upon the exercise of the underwriters’ overallotment option, which was exercised in full, at a public offering price of $10.00 per unit, resulting in gross proceeds of $276 million. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants are exercisable. The units began trading on the NYSE under the symbol “TINV.U” on November 24, 2020. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the NYSE under the symbols “TINV” and “TINV WS,” respectively.

The Company is led

Read More

Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares


SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters’ option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai’s Class A common stock began trading on the Nasdaq Global Select Market on November 20, 2020 under the symbol “MRVI.”

Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. BofA Securities,

Read More

Pine Island Acquisition Corp. Announces Partial Exercise and Closing of Underwriters’ Option to Purchase Additional Units in Connection with its Initial Public Offering


FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Pine Island Acquisition Corp. (the “Company”) today announced that the underwriters of its previously announced initial public offering of 20,000,000 units, which closed on November 19, 2020, have partially exercised their option to purchase additional units, resulting in the issuance of an additional 1,838,800 units at a public offering price of $10.00 per unit. After giving effect to the partial exercise and close of the option, an aggregate of 21,838,800 units have been issued in the initial public offering and an aggregate of $218,388,000 has been deposited into the Company’s trust account. The underwriters have until December 31, 2020 to exercise the remainder of their option to purchase additional units.

Each unit consists of one share of the Company’s Class A common stock and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A

Read More

Telos Corporation Completes Initial Public Offering and Announces Exercise of Over-Allotment


ASHBURN, Va., Nov. 24, 2020 (GLOBE NEWSWIRE) — Telos® Corporation (“Telos”), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, announced the closing of its upsized initial public offering of 14,968,859 shares of common stock. The offering was priced at $17.00 per share, resulting in gross proceeds of $254,470,603. Telos’s shares began trading on the Nasdaq Global Market on November 19, 2020 under the Ticker Symbol “TLS.”

B. Riley Securities, BMO Capital Markets, and Needham & Company acted as joint bookrunners for the offering. Colliers Securities LLC, D.A. Davidson & Co., Northland Capital Markets, Wedbush Securities, and MKM Partners served as co-managers for the offering. The underwriters yesterday elected to exercise the 30-day option, granted by Telos, to purchase an additional 2,245,328 shares of common stock at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments. After giving effect

Read More

NeoGames Announces Closing of $94.0 Million Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option


LUXEMBOURG, Nov. 24, 2020 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery solutions, announced today the closing of its initial public offering of 5,528,650 ordinary shares at a price of $17.00 per ordinary share, including 721,128 ordinary shares sold pursuant to the full exercise of the underwriters’ overallotment option. The offering consisted of 2,987,625 ordinary shares offered by the Company and 2,541,025 ordinary shares offered by certain selling shareholders. The shares began trading on The Nasdaq Global Market under the ticker symbol “NGMS” on November 19, 2020.

Stifel acted as the lead bookrunner for the offering and as representative of the underwriters, and Macquarie Capital and Truist Securities acted as joint bookrunners for the offering.

A registration statement on Form F-1 relating to these securities was declared effective by the U.S. Securities and Exchange Commission on November 18, 2020. This offering

Read More

Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares


SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Olema Oncology from the offering were approximately $240.4 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on November 19, 2020, under the ticker symbol “OLMA.”

J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC acted as active joint book-running managers for the offering. Canaccord Genuity

Read More

Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares


SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Olema Oncology from the offering were approximately $240.4 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on November 19, 2020, under the ticker symbol “OLMA.”

J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC acted as active joint book-running managers for the offering. Canaccord Genuity

Read More

Moderna announces initial Phase 3 data showing its COVID-19 vaccine is up to 94.5% effective


Moderna’s vaccine can be stored in a standard refrigerator, unlike Pfizer’s.

In another promising medical development, the biotechnology company Moderna has announced its COVID-19 vaccine could be up to 94.5% effective.

The news comes a week after Pfizer announced its vaccine could be up to 90% effective based on a similar, early analysis from its Phase 3 trial.

In a release Monday, Moderna said its Phase 3 trial “met statistical criteria with a vaccine efficacy of 94.5%,” according to an early analysis of the data that included 95 participants with confirmed cases of COVID-19.

Read More